Biovica International
1.114
SEK
-7.17 %
Less than 1K followers
BIOVIC B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
-7.17%
-44.13%
-44.3%
-48.31%
-59.56%
-52.8%
-95.32%
-87.78%
-89.98%
Biovica International is a pharmaceutical company that focuses its research on cancer treatments. The company is developing methods for measuring cell proliferation, where the test is taken via blood samples. The tests analyze the risk for the development of the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main area of focus is within treatment of breast cancer. The company was founded in 2008 and is headquartered in Uppsala.
Read moreMarket cap
108.93M SEK
Turnover
1.14M SEK
Revenue
7.29M
EBIT %
-1,740.05 %
P/E
-
Dividend yield-%
-
Financial calendar
18/6
2025
Annual report '25
11/9
2025
Interim report Q1'26
16/9
2025
General meeting '25
All
Webcasts
Press releases
3rd party
ShowingAll content types
Biovica Q3 Interim report Nov 2024 - Jan 2025
Biovica Delårsrapport 3 Nov 2024 -Jan 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools